Is megestrol acetate safe and effective for malnourished nursing home residents? by Wen, Frances K. et al.
Evidence-based answers from the 
Family Physicians Inquiries Network
112 THE JOURNAL OF FAMILY PRACTICE  |   FEBRUARY 2018  |   VOL 67, NO 2
CLINICAL INQUIRIES
EVIDENCE-BASED ANSWER
A
Frances K. Wen, PhD; 
James Millar, MD
University of Oklahoma 
School of Community 
Medicine, Tulsa
Linda Oberst-Walsh, MD 
University of Colorado 
School of Medicine, Denver
Joan Nashelsky, MLS 
Family Physicians Inquiries 
Network, Iowa City
DEPUTY EDITOR
Rick Guthmann, MD, 
MPH
Advocate Illinois Masonic 
Family Medicine Residency, 
Chicago
Q Is megestrol acetate safe and 
effective for malnourished  
nursing home residents?
 no. Megestrol acetate (MA) is 
 neither safe nor effective for stimu-
lating appetite in malnourished nursing 
home residents. It increases the risk of deep 
vein thrombosis (DVT) (strength of recom-
mendation [SOR]: C, 2 retrospective chart 
reviews), but isn’t associated with other new 
or worsening events or disorders (SOR: B, 
single randomized controlled trial [RCT]).
Over a 25-week period, MA wasn’t as-
sociated with increased mortality (SOR: B, 
single RCT). After 44 months, however, 
MA-treated patients showed decreased 
median survival (SOR: B, single case- 
control study). 
Consistent, meaningful weight gain 
was not observed with MA treatment 
(SOR: B, single case-control study, single 
RCT, 2 retrospective chart reviews, single 
prospective case-series). 
Evidence summary 
A 25-week double-blind, placebo-controlled 
RCT of 51 nursing home patients (mean age 
76 years, range 50 to 95 years; 96% men) in 
2000 found no difference in all-cause mor-
tality between the MA treatment group and 
the placebo group (absolute risk reduction 
[ARR]=13.4%; 95% confidence interval [CI], 
-12.9% to 37.3%; number needed to harm 
[NNH]=7; 95% CI, -8 to 3).1
A 2007 case-control study of 17,328 nur- 
sing home residents (mean age 84 years 
[standard deviation, 9]; 71% women) found 
increased mortality for residents treated 
with at least 6 days of MA (median survival= 
23.9 months; 95% CI, 20.2-27.5) compared 
with untreated residents (median survival= 
31.2 months; 95% CI, 27.8-35.9).2 The de-
crease in median survival remained after 
adjusting for demographic variables, medi-
cal diagnoses, and cognitive and physi-
cal functioning (hazard ratio=1.37; 95% CI, 
1.17-1.59). Follow-up ranged from 30 days to 
44 months. 
Risks related to megestrol acetate  
include deep vein thrombosis
The 2000 double-blind, placebo-controlled 
RCT of 51 nursing home patients found no 
difference in adverse events between the MA 
group and the placebo group (absolute risk 
increase=6.3%; 95% CI, -14.7% to 27.3%).1 No 
DVTs were reported as adverse events.
A 2003 retrospective chart review of 
246 nursing home residents (mean age 
87 years, 77% women) who were given MA 
400 mg/d found an overall incidence of DVT 
of 4.1% (10 residents); 3.2% (8) residents were 
on MA at the time of DVT occurrence.3 
A 2000 retrospective chart review of 
19 nursing home residents who were pre-
scribed MA (mean age 83 years, range 66 to 
92 years; 84% women) found 32% (6) who 
developed Doppler-confirmed DVT after 
50 days of therapy.4 DVT was not associated 
with known risk factors, age, body mass in-
dex, numbers of medications, or other medi-
cal diagnoses. The authors didn’t report MA 
dosage.
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Patients on megestrol acetate  
don’t gain weight...
The 2000 double-blind, placebo-controlled 
RCT of 51 nursing home patients found no 
difference between the MA (800 mg/d for 
12 weeks) and placebo groups in percentage 
of patients who gained ≥1.82 kg (ARR=-6.6%; 
95% CI, -30.2% to 18.2%).1 At the 25-week 
follow-up (after the MA patients had been 
off the therapy for 13 weeks), a statistically, 
but not clinically, significant difference was 
observed in the number of MA patients 
who gained ≥1.82 kg (absolute benefit in-
crease=40.2%; 95% CI, 13.4%-66.9%; num-
ber needed to treat [NNT]=2; 95% CI, 1-8). 
Of note, the authors based their statistics on 
a weight gain of ≥1.82 kg whereas 5 kg or 5% 
weight gain is the more commonly used defi-
nition for clinical significance.5 
The 2007 case-control cohort study of 
17,328 nursing home residents, who had lost 
5% of total body weight in 3 months or 10% of 
total body weight in 6 months, also found no 
significant difference in weight gain between 
MA-treated patients (median dose=486 mg, 
range 20 to 2400 mg; median duration= 
90 days, range 7 to 934 days; median change= 
1 lb, interquartile range [IQR]=-8 to 10) and 
controls (median change=2 lb, IQR=-4 to 9) 
after 6 months of treatment.2 
...And some lose weight
In a 2005 prospective case series of 17 nur- 
sing home residents (mean age 92 years [stan-
dard deviation, 6], 88% women), MA (400 mg/d 
for 63 days) was associated with weight loss 
(mean=-2.13±9.32 lb).6 Nine patients (53%) lost 
weight (mean=9.3±5.4 lb), and 8 patients (47%) 
gained weight (mean=5.9±4.9 lb).
A retrospective chart review in 2000 of 
14 nursing home residents (mean age 
84 years, range 74 to 97 years; 85% women) 
who received MA 40 to 800 mg/d for one to 
15 weeks showed that 43% gained weight 
(mean=3.1 kg), 43% lost weight (mean= 
2.0 kg), and 14% had no weight change.7
A 2002 retrospective chart review of 
50 nursing home residents (mean age 
79 years, range 31 to 93 years; 74% women) 
who were treated with MA 200 to 2400 mg/d 
for at least 6 months found a mean weight loss 
of 1.1 to 2.2 kg.8 In the 6 months after MA dis-
continuation, weight gain for available sub-
jects (5 to 16 patients) varied (mean monthly 
change=-0.17 kg to 3.07 kg). The study had 
a high attrition rate (26 patients were lost 
6 months after MA initiation; 39 were lost 
6 months after MA discontinuation).  
Recommendations
The 2015 American Geriatrics Society Beers 
Criteria for potentially inappropriate medi-
cation use in older adults strongly advises 
against the use of MA because of limited in-
creases in weight and increased risk of throm-
botic events.9                   JFP
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